Login
Products
Login
Home
Alerts
Search
Watchlist
Products

Krishna Institute of Medical Sciences Ltd

KIMS
NSE
665.25
0.45%
Last Updated:
29 Apr '26, 4:00 PM
Company Overview
Guidance Tracker
Alert
Watchlist
Note

Krishna Institute of Medical Sciences Ltd

KIMS
NSE
665.25
0.45%
29 Apr '26, 4:00 PM
Company Overview
Guidance Tracker
Add Alert
Add to Watchlist
Edit Note
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
26,619Cr
Close
Close Price
665.25
Industry
Industry
Hospitals
PE
Price To Earnings
88.70
PS
Price To Sales
7.34
Revenue
Revenue
3,627Cr
Rev Gr TTM
Revenue Growth TTM
26.29%
PAT Gr TTM
PAT Growth TTM
-17.08%
Peer Comparison
How does KIMS stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
KIMS
VS

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue
RevenueCr
576606652606634688777772797872961998
Growth YoY
Revenue Growth YoY%
54.722.315.77.810.113.619.127.525.726.623.629.2
Expenses
ExpensesCr
413449475459475509559585599679757799
Operating Profit
Operating ProfitCr
163157177147159179218187198193204199
OPM
OPM%
28.325.927.224.325.126.128.124.224.922.121.219.9
Other Income
Other IncomeCr
53334551815745
Interest Expense
Interest ExpenseCr
599121618202627334557
Depreciation
DepreciationCr
353233354639414553536679
PBT
PBTCr
1271191391021001271621351341149769
Tax
TaxCr
293237262932424228292517
PAT
PATCr
998710177729512193106857252
Growth YoY
PAT Growth YoY%
18.49.4-4.5-6.5-27.59.819.220.848.4-10.7-40.4-43.9
NPM
NPM%
17.114.315.512.611.313.815.512.013.39.87.55.2
EPS
EPS
2.32.02.31.81.62.22.72.22.52.01.71.3

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue
RevenueCr
6649181,1231,3301,6512,1982,4983,0353,627
Growth
Revenue Growth%
38.322.318.524.133.113.721.519.5
Expenses
ExpensesCr
5988378789591,1351,5941,8612,2522,833
Operating Profit
Operating ProfitCr
6681245371516604637783794
OPM
OPM%
9.98.821.827.931.227.525.525.821.9
Other Income
Other IncomeCr
3766103041164332
Interest Expense
Interest ExpenseCr
8346403316314790161
Depreciation
DepreciationCr
4056717073129147177251
PBT
PBTCr
-20-15141279457485460558413
Tax
TaxCr
2634257411311912414398
PAT
PATCr
-46-49115205344366336415315
Growth
PAT Growth%
-5.2336.878.667.36.4-8.223.5-24.1
NPM
NPM%
-7.0-5.310.315.420.816.613.413.78.7
EPS
EPS
-9.4-6.916.026.98.48.47.89.67.5

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
Equity CapitalCr
507474788080808080
Reserves
ReservesCr
-2094665237861,3071,5901,7482,0582,190
Current Liabilities
Current LiabilitiesCr
7492012192782152964528361,146
Non Current Liabilities
Non Current LiabilitiesCr
3473513662822827071,3072,4812,904
Total Liabilities
Total LiabilitiesCr
9581,1181,1961,4361,9072,9413,8525,7366,625
Current Assets
Current AssetsCr
156174220451393478547697823
Non Current Assets
Non Current AssetsCr
8029449769851,5142,4643,3045,0395,802
Total Assets
Total AssetsCr
9581,1181,1961,4361,9072,9413,8525,7366,625

Cash Flow

Consolidated
Standalone
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow
Operating Cash FlowCr
106134202356324432521582
Investing Cash Flow
Investing Cash FlowCr
-64-110-125-354-412-547-753-1,116
Financing Cash Flow
Financing Cash FlowCr
-39-27-44106120217543
Net Cash Flow
Net Cash FlowCr
3-33212-27-95-159
Free Cash Flow
Free Cash FlowCr
4957150262154-140-125-380
CFO To PAT
CFO To PAT%
-229.0-275.6175.1173.294.3118.1155.1140.3
CFO To EBITDA
CFO To EBITDA%
161.5165.482.396.062.871.581.874.3

Ratios

Consolidated
Standalone
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
000011,04311,25416,47125,581
Price To Earnings
Price To Earnings
0.00.00.00.033.233.553.166.5
Price To Sales
Price To Sales
0.00.00.00.06.75.16.68.4
Price To Book
Price To Book
0.00.00.00.08.06.79.012.0
EV To EBITDA
EV To EBITDA
4.83.71.10.121.519.627.935.8
Profitability Ratios
Profitability Ratios
GPM
GPM%
75.777.177.478.378.578.178.879.3
OPM
OPM%
9.98.821.827.931.227.525.525.8
NPM
NPM%
-7.0-5.310.315.420.816.613.413.7
ROCE
ROCE%
37.33.619.526.428.822.015.913.8
ROE
ROE%
29.1-9.019.323.824.821.918.419.4
ROA
ROA%
-4.8-4.39.614.318.012.48.77.2
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
### **Overview** Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) is one of India's largest and fastest-growing corporate healthcare providers. Headquartered in Hyderabad, Telangana, and founded in 2000 by Dr. B. Bhaskar Rao, a renowned cardiothoracic surgeon, the company has evolved from a single hospital in Nellore, Andhra Pradesh, into a pan-Indian healthcare network. KIMS is focused on delivering **affordable, high-quality tertiary and quaternary care** through a **multi-specialty, integrated model** supported by advanced technology and clinical innovation. Listed on Indian stock exchanges since 2021, KIMS leverages a hybrid growth strategy combining **organic expansions, strategic acquisitions, and partnerships**, with a strong emphasis on **doctor equity participation, technology adoption, and scale leadership**. --- ### **Network & Scale (As of Aug 2025)** - **25 hospitals** across 5 states: **Telangana, Andhra Pradesh, Maharashtra, Kerala, and Karnataka**. - **Over 8,000 operational beds**, with a total network capacity expected to exceed **10,000 beds** post-expansion. - **~1,800 incremental beds** under development across key locations, including: - **Bangalore (Project-1 & 2):** 800 beds (combined) - **Kondapur (Telangana):** 500 beds - **Rajahmundry (Andhra Pradesh):** 350 beds - Over **1,600 doctors** and **10,000+ employees** network-wide. --- ### **Clinical Capabilities & Specialties** KIMS offers comprehensive care across **25+ specialties**, with a focus on high-complexity, capital-intensive services: - **Cardiac Sciences** - **Oncology** (including dedicated cancer centers in Ongole, Anantapur, and planned in Bangalore) - **Neurosciences & Epilepsy Care** - **Organ Transplantation** (Heart, Lung, Liver, Kidney) – **190 lung transplants in 3 years**, **national record**. - **Orthopedics & Robotic Joint Replacements** – Acquired **Sunshine Hospitals**, South Asia’s second-largest orthopedic center with 10,000+ annual surgeries. - **Mother & Child Care** (Cuddles brand expansion in multiple cities) - **Gastroenterology & Transplant Hepatology** - **Renal Sciences and Nephrology** #### **Advanced Technology & First-in-India Procedures** - **South Asia’s first and India’s only TULSA-PRO** center for **MRI-guided, incision-free prostate treatment** (benign prostatic hyperplasia and localized cancer). - **Robotic Surgery Program**: KIMS-Kingsway (Nagpur) has performed **50 Da Vinci robotic-assisted surgeries**, offering **minimally invasive procedures** with faster recovery. - **MR-Guided Focused Ultrasound (MRgFUS)** for **non-invasive treatment** of essential tremors and Parkinson’s. Achieved **100% success rate** in early patient cases. - **Omniscient Neuro-technology brain mapping** for enhanced surgical precision in neurosurgery. - **Elekta radiation therapy systems** worth **USD 38–40 million**, deployed across facilities to **upgrade oncology capabilities**. --- ### **Geographic Expansion Strategy** KIMS is aggressively expanding beyond its traditional stronghold in Telangana and Andhra Pradesh to **de-risk regional concentration** and tap into underserved markets. #### **Recent Expansions (Aug 2025)** - **Karnataka**: Entered with **two hospitals in Bangalore (Mahadevpur & Electronic City)** with ~800 beds total. Plans to expand into **Sarjapur and northern Bangalore (750–1,000 beds)**. - **EBITDA neutrality expected at 30–40% occupancy**, pending timely **doctor onboarding and insurance empanelment**. - **Kerala**: Acquired **Sreechand Hospital (Kannur)** and signed O&M agreements with **Westfort Hi-Tech Hospital (Thrissur)**. Launched units in **Kollam, Kannur, and Kozhikode**. - Future **800-bed health cities** planned in **Kochi and Kozhikode**. - Focus on **transplant services** and **oncology** in Tier 2/3 cities. - **Maharashtra**: Operational presence in **Nagpur, Nashik, and Thane**. - **Sangli and Guntur** hospitals are **breakeven**, each generating **INR 17–18 crores/month**. - Thane, Nashik, and Kollam generate **INR 5.5, 15.5, and 9 crores/monthly revenue**, respectively. #### **O&M (Operations & Management) Model** - Controls **P&L, clinical hiring, and operations** in partner-owned facilities. - Operates **3 O&M hospitals** (Hyderabad, Thrissur, Sangli), with **1 more planned in Telangana**. - Minimizes capital risk while expanding market presence. - **Kompally hospital (Hyderabad)** under O&M with **no operational cost to KIMS**. --- ### **Strategic Initiatives** - **Expansion into Tier 2 & 3 Cities**: Leverages lower competition, high unmet demand, and strong brand recall in Telugu-speaking regions (Andhra, Telangana, Karnataka, Maharashtra). - **Cluster-Based Development**: Focused on creating **integrated healthcare hubs** in urban clusters (e.g., Hyderabad, Bangalore, Nagpur). - **Digital Health & Wellness**: Investing in **telemedicine, preventive diagnostics**, and **online care platforms** to tap post-COVID wellness demand. - **Research & Academia**: - **KIMS Foundation & Research Centre (KFRC)** – NAC-SCRT accredited for stem cell research. - Collaborations with **ICMR, IIPH, University of Hyderabad** on clinical trials and patient registries. - **Leadership & Talent**: - Appointed veteran leaders: **Dr. Nitish Shetty (Bangalore Cluster)**, **Mr. Farhaan Yaseen (Kerala Cluster)**, **Mr. Sreenath Reddy (Kerala & Karnataka)**. - Focus on **retention of top consultants** via equity participation (>80% doctor retention since inception).